Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Almagate in pregnant women with heartburn or reflux
2024-515381-14-00Phase 4Authorised
- Sponsor
- Almirall
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aluminium magnesium carbonate in gastroesophageal reflux disease (GERD), sponsored by Almirall. Primary endpoints: Gestational diabetes, Hypertensive states of pregnancy and 5 more. Planned start Oct 2024; status: authorised.
02
Drugs
aluminium magnesium carbonate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2024-515381-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515381-14-00.